These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11932941)

  • 1. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice.
    Bian F; Nath R; Sobocinski G; Booher RN; Lipinski WJ; Callahan MJ; Pack A; Wang KK; Walker LC
    J Comp Neurol; 2002 May; 446(3):257-66. PubMed ID: 11932941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice.
    Leroy K; Bretteville A; Schindowski K; Gilissen E; Authelet M; De Decker R; Yilmaz Z; Buée L; Brion JP
    Am J Pathol; 2007 Sep; 171(3):976-92. PubMed ID: 17690183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.
    Cruz JC; Tseng HC; Goldman JA; Shih H; Tsai LH
    Neuron; 2003 Oct; 40(3):471-83. PubMed ID: 14642273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain.
    Takashima A; Murayama M; Yasutake K; Takahashi H; Yokoyama M; Ishiguro K
    Neurosci Lett; 2001 Jun; 306(1-2):37-40. PubMed ID: 11403952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cdk5 is a key factor in tau aggregation and tangle formation in vivo.
    Noble W; Olm V; Takata K; Casey E; Mary O; Meyerson J; Gaynor K; LaFrancois J; Wang L; Kondo T; Davies P; Burns M; Veeranna ; Nixon R; Dickson D; Matsuoka Y; Ahlijanian M; Lau LF; Duff K
    Neuron; 2003 May; 38(4):555-65. PubMed ID: 12765608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation.
    Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
    Biochem Biophys Res Commun; 2002 Nov; 298(5):693-8. PubMed ID: 12419309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles.
    Augustinack JC; Sanders JL; Tsai LH; Hyman BT
    J Neuropathol Exp Neurol; 2002 Jun; 61(6):557-64. PubMed ID: 12071639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.
    Li G; Faibushevich A; Turunen BJ; Yoon SO; Georg G; Michaelis ML; Dobrowsky RT
    J Neurochem; 2003 Jan; 84(2):347-62. PubMed ID: 12558997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.
    Patrick GN; Zukerberg L; Nikolic M; de la Monte S; Dikkes P; Tsai LH
    Nature; 1999 Dec; 402(6762):615-22. PubMed ID: 10604467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
    Wang JZ; Grundke-Iqbal I; Iqbal K
    Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.
    Shukla V; Skuntz S; Pant HC
    Arch Med Res; 2012 Nov; 43(8):655-62. PubMed ID: 23142263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles.
    Tandon A; Yu H; Wang L; Rogaeva E; Sato C; Chishti MA; Kawarai T; Hasegawa H; Chen F; Davies P; Fraser PE; Westaway D; St George-Hyslop PH
    J Neurochem; 2003 Aug; 86(3):572-81. PubMed ID: 12859671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cdk5 as a drug target for the treatment of Alzheimer's disease.
    Lau LF; Seymour PA; Sanner MA; Schachter JB
    J Mol Neurosci; 2002 Dec; 19(3):267-73. PubMed ID: 12540052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice.
    Piedrahita D; Hernández I; López-Tobón A; Fedorov D; Obara B; Manjunath BS; Boudreau RL; Davidson B; Laferla F; Gallego-Gómez JC; Kosik KS; Cardona-Gómez GP
    J Neurosci; 2010 Oct; 30(42):13966-76. PubMed ID: 20962218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration.
    Pei JJ; Grundke-Iqbal I; Iqbal K; Bogdanovic N; Winblad B; Cowburn RF
    Brain Res; 1998 Jun; 797(2):267-77. PubMed ID: 9666145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro.
    Town T; Zolton J; Shaffner R; Schnell B; Crescentini R; Wu Y; Zeng J; DelleDonne A; Obregon D; Tan J; Mullan M
    J Neurosci Res; 2002 Aug; 69(3):362-72. PubMed ID: 12125077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.
    Ahlijanian MK; Barrezueta NX; Williams RD; Jakowski A; Kowsz KP; McCarthy S; Coskran T; Carlo A; Seymour PA; Burkhardt JE; Nelson RB; McNeish JD
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2910-5. PubMed ID: 10706614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex.
    Hamdane M; Sambo AV; Delobel P; Bégard S; Violleau A; Delacourte A; Bertrand P; Benavides J; Buée L
    J Biol Chem; 2003 Sep; 278(36):34026-34. PubMed ID: 12826674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
    Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
    J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase 5 immunoreactivity for granulovacuolar degeneration.
    Nakamori M; Takahashi T; Yamazaki Y; Kurashige T; Yamawaki T; Matsumoto M
    Neuroreport; 2012 Oct; 23(15):867-72. PubMed ID: 22968343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.